Because, time is what we need!!!!
ENV105, a monoclonal antibody, is showing promise for treating castrate-resistant prostate cancer (CRPC) by targeting CD105, a protein linked to tumor resistance. By disrupting the BMP/CD105 signaling pathway, ENV105 enhances the effectiveness of androgen receptor inhibitors like apalutamide.
In a Phase 2 trial, ENV105 demonstrated a 62% clinical benefit rate in patients with limited treatment options. T
he ongoing study aims to assess its impact on PSA levels and tumor reduction, with interim safety results expected in early 2025. If successful, ENV105 could become a crucial tool in overcoming resistance in prostate cancer treatment.
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance, Int J Mol Sci. 2022 Nov; 23(21): 13521
Supraphysiological Androgens [SPA] Promote Tumor Suppressive Activity of the AR Through cMYC Repression and Recruitment of the DREAM Complex
Seminal Vesicle Invasion & Senescent tumor cells.